Share on StockTwits

Furiex Pharmaceuticals (NASDAQ:FURX) CFO Sailash Patel sold 1,504 shares of the stock on the open market in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $104.68, for a total transaction of $157,438.72. Following the completion of the transaction, the chief financial officer now directly owns 26,444 shares in the company, valued at approximately $2,768,158. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Furiex Pharmaceuticals (NASDAQ:FURX) traded down 0.34% on Thursday, hitting $104.63. 331,694 shares of the company’s stock traded hands. Furiex Pharmaceuticals has a one year low of $32.05 and a one year high of $121.97. The stock’s 50-day moving average is $102.1 and its 200-day moving average is $77.80. The company’s market cap is $1.131 billion.

Furiex Pharmaceuticals (NASDAQ:FURX) last announced its earnings results on Wednesday, May 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was down 83.7% on a year-over-year basis. On average, analysts predict that Furiex Pharmaceuticals will post $-2.57 earnings per share for the current fiscal year.

Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.